Breaking News Instant updates and real-time market news.

VKTX

Viking Therapeutics

$11.15

0.91 (8.89%)

, MDGL

Madrigal Pharmaceuticals

$313.25

31.25 (11.08%)

07:44
06/14/18
06/14
07:44
06/14/18
07:44

H.C. Wainwright says don't forget about Viking with Madrigal in play

After Bloomberg reported that Madrigal Pharmaceuticals (MDGL) is exploring a sale after receiving takeover interest, H.C. Wainwright analyst Joseph Pantginis tells investors to not forget about Viking Therapeutics (VKTX). The latter's potential treatment for non-alcoholic steatohepatitis, VK2809, could be even better than Madrigal's, Pantginis contends. The analyst believes that with Madrigal in play, it continues to bring "deserved focus to VK2809, which should garner significant business development interest as well." The analyst thinks VK2809 is "just starting to realize its underlying value from an investment standpoint." Citing the market potential for VK2809 and VK5211, the analyst highlights the value disconnect when comparing Madrigal's market capitalization of $4.8B with Viking's at $652M. Pantginis keeps a Buy rating on Viking Therapeutics with a $15 price target.

VKTX

Viking Therapeutics

$11.15

0.91 (8.89%)

MDGL

Madrigal Pharmaceuticals

$313.25

31.25 (11.08%)

VKTX Viking Therapeutics
$11.15

0.91 (8.89%)

06/01/18
HCWC
06/01/18
NO CHANGE
Target $15
HCWC
Buy
Viking Therapeutics price target raised to $15 from $11 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Viking Therapeutics (VKTX) to $15 saying the data yesterday from Madrigal Pharmaceuticals (MDGL) validate the thyroid receptor beta approach and derisks the VK2809 Phase 2 outcome. The analyst keeps a Buy rating on shares of Viking Therapeutics.
06/01/18
MAXM
06/01/18
NO CHANGE
Target $14
MAXM
Buy
Viking Therapeutics price target raised to $14 from $8 at Maxim
Maxim analyst Jason McCarthy raised his price target for Viking Therapeutics (VKTX) to $14 from $8 saying the data yesterday from Madrigal Pharmaceuticals (MDGL) suggests that this class of Thyroid Hormone Receptor Beta agonist may be a successful treatment for NASH and that Viking's VK2809 could have similar success.
06/01/18
ROTH
06/01/18
NO CHANGE
Target $13
ROTH
Buy
Viking Therapeutics price target raised to $13 from $7.50 at Roth Capital
Roth Capital analyst Scott Henry maintained a Buy rating on Viking Therapeutics while raising his price target to $13 from $7.50 saying the data yesterday from Madrigal Pharmaceuticals (MDGL) appears to validate the class of Thyroid Hormone Receptor Beta agonist compounds, noting that Viking's VK2809 is a similar agonist. In a research note to investors, Henry said he assumes that enrollment for VK2809 in a Phase 2 trial to treat NAFLD/hypercholesterolemia will be completed this month with a data readout in about October, and, assuming the readout is positive, Viking will meet with the FDA to determine the next steps. Henry believes the company may look to move directly to a phase 2/3 sequential trial.
06/05/18
MAXM
06/05/18
NO CHANGE
Target $14
MAXM
Buy
Chances of beta agonist success favors Viking Therapeutics, says Maxim
After Viking Therapeutics (VKTX) announced that enrollment has been completed in the company's ongoing Phase 2 clinical trial of VK2809 in patients with primary hypercholesterolemia and non-alcoholic fatty liver disease, Maxim analyst Jason McCarthy said that given Viking's prior data and the data for Madrigal's (MDGL) MGL-3196, which is in the same class of Thyroid Hormone Receptor beta agonists, that he believes the probability of success favors Viking. He maintains a Buy rating and $14 price target on Viking shares.
MDGL Madrigal Pharmaceuticals
$313.25

31.25 (11.08%)

06/07/18
EVER
06/07/18
NO CHANGE
Target $300
EVER
Outperform
Evercore ISI 'comfortable' with $300 price target on Madrigal after secondary
Evercore ISI analyst Josh Schimmer said he remains "comfortable" with his $300 price target on Madrigal Pharmaceuticals despite the stock trading off following the company's secondary offering of stock. After fielding calls from investors, Schimmer thinks a lack of catalysts "is probably the number one concern," as the company hopes to be able to start a Phase 3 NASH trial by year-end, which "probably means a 2-3 year void of news flow." Schimmer also listed long-term safety and efficacy and competitive dynamics as concerns voiced by investors he spoke with. He maintains an Outperform rating on Madrigal, which dropped over 10% in today's trading to about $281 per share.
06/12/18
MAXM
06/12/18
NO CHANGE
Target $30
MAXM
Buy
Galmed price target raised to $30 from $14 at Maxim
Maxim analyst Jason McCarthy raised his outyear estimates for Aramchol and reduced his risk adjustment to 15% from 30% following the announcement of Galmed's (GLMD) Phase 2b data for Aramchol in NASH. Given the changes, he raised his price target on Galmed shares to $30 from $14, which he notes implies a market capitalization of $450M. That valuation may be viewed as "conservative" given the rise in valuations of others in the NASH space, including Madrigal (MDGL), which McCarthy said completed a Phase 2 study that was "smaller and shorter" than Galmed. He maintains a Buy rating on Galmed shares, which are up $13, or 185% to about $20 per share in afternoon trading.

TODAY'S FREE FLY STORIES

KMX

CarMax

$71.05

-1.77 (-2.43%)

07:39
06/22/18
06/22
07:39
06/22/18
07:39
Earnings
CarMax reports Q1 EPS $1.33, consensus $1.24 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$73.94

-0.785 (-1.05%)

07:37
06/22/18
06/22
07:37
06/22/18
07:37
Downgrade
Nike rating change  »

Nike downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

AYX

Alteryx

$38.63

-1.21 (-3.04%)

07:36
06/22/18
06/22
07:36
06/22/18
07:36
Initiation
Alteryx initiated  »

Alteryx initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALBO

Albireo Pharma

$36.05

1.05 (3.00%)

07:36
06/22/18
06/22
07:36
06/22/18
07:36
Conference/Events
Albireo Pharma management to meet with Needham »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

INTC

Intel

$52.19

-1.27 (-2.38%)

, JPM

JPMorgan

$107.52

-0.04 (-0.04%)

07:35
06/22/18
06/22
07:35
06/22/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

INTC

Intel

$52.19

-1.27 (-2.38%)

JPM

JPMorgan

$107.52

-0.04 (-0.04%)

MS

Morgan Stanley

$49.78

-0.095 (-0.19%)

PG

Procter & Gamble

$76.44

0.59 (0.78%)

LUV

Southwest

$53.15

1.16 (2.23%)

PAGS

PagSeguro Digital

$29.42

0.91 (3.19%)

COTY

Coty

$14.48

0.03 (0.21%)

HBI

Hanesbrands

$22.04

0.615 (2.87%)

SYK

Stryker

$169.81

0.21 (0.12%)

ECA

Encana

$12.19

-0.235 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

  • 13

    Jul

  • 24

    Jul

  • 26

    Jul

  • 12

    Oct

  • 22

    Jun

SRPT

Sarepta

$149.57

-4.12 (-2.68%)

07:34
06/22/18
06/22
07:34
06/22/18
07:34
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBIO

iBio

$0.95

-0.12 (-11.22%)

07:33
06/22/18
06/22
07:33
06/22/18
07:33
Syndicate
iBio raises $16M in a public offering »

The securities offered by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$462.87

-2.66 (-0.57%)

07:33
06/22/18
06/22
07:33
06/22/18
07:33
Periodicals
Chipotle will test new menu items, strategy, NY Times reports »

Chipotle is adding five…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 26

    Jul

ABBV

AbbVie

$95.55

-2.72 (-2.77%)

07:33
06/22/18
06/22
07:33
06/22/18
07:33
Recommendations
AbbVie analyst commentary  »

AbbVie most exposed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEA

Lear

$198.83

-2.565 (-1.27%)

07:32
06/22/18
06/22
07:32
06/22/18
07:32
Conference/Events
Lear to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

, NXPI

NXP Semiconductors

$112.55

-0.42 (-0.37%)

07:31
06/22/18
06/22
07:31
06/22/18
07:31
Hot Stocks
Qualcomm extends cash offer for NXP Semiconductors to June 29 »

Qualcomm (QCOM) announced…

QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

NXPI

NXP Semiconductors

$112.55

-0.42 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

  • 12

    Jul

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

, RIG

Transocean

$11.94

-0.575 (-4.60%)

07:30
06/22/18
06/22
07:30
06/22/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

RIG

Transocean

$11.94

-0.575 (-4.60%)

CSX

CSX

$64.06

-0.81 (-1.25%)

Z

Zillow

$61.83

-2.84 (-4.39%)

KMB

Kimberly-Clark

$100.15

-1.51 (-1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

WSC

Williams Scotsman

$12.10

-0.3 (-2.42%)

07:30
06/22/18
06/22
07:30
06/22/18
07:30
Hot Stocks
Breaking Hot Stocks news story on Williams Scotsman »

WillScot Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SENS

Senseonics

$4.96

0.1 (2.06%)

07:29
06/22/18
06/22
07:29
06/22/18
07:29
Recommendations
Senseonics analyst commentary  »

Senseonics FDA approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

CAKE

Cheesecake Factory

$59.87

2.13 (3.69%)

07:28
06/22/18
06/22
07:28
06/22/18
07:28
Downgrade
Cheesecake Factory rating change  »

Cheesecake Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSC

Williams Scotsman

$12.10

-0.3 (-2.42%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Conference/Events
Williams Scotsman to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SLNO

Soleno Therapeutics

$2.34

-0.02 (-0.85%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Initiation
Soleno Therapeutics initiated  »

Soleno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTD

Trade Desk

$91.53

-1.84 (-1.97%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Recommendations
Trade Desk analyst commentary  »

Trade Desk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRTX

Heron Therapeutics

$40.00

9.3 (30.29%)

07:25
06/22/18
06/22
07:25
06/22/18
07:25
Recommendations
Heron Therapeutics analyst commentary  »

Heron Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

KLAC

KLA-Tencor

$110.31

0.54 (0.49%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Downgrade
KLA-Tencor rating change  »

KLA-Tencor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$165.62

-3.64 (-2.15%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Recommendations
Red Hat analyst commentary  »

Red Hat price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

CSCO

Cisco

$43.17

-0.58 (-1.33%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Recommendations
Cisco analyst commentary  »

Cisco selloff brings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 12

    Jul

TNDM

TNDM

, DXCM

DexCom

$99.72

-0.88 (-0.87%)

07:23
06/22/18
06/22
07:23
06/22/18
07:23
Recommendations
TNDM, DexCom analyst commentary  »

Tandem Diabetes'…

TNDM

TNDM

DXCM

DexCom

$99.72

-0.88 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

DRI

Darden

$107.07

13.8 (14.80%)

07:22
06/22/18
06/22
07:22
06/22/18
07:22
Recommendations
Darden analyst commentary  »

Darden price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 16

    Jul

  • 17

    Jul

VSLR

Vivint Solar

$5.00

-0.05 (-0.99%)

07:20
06/22/18
06/22
07:20
06/22/18
07:20
Upgrade
Vivint Solar rating change  »

Vivint Solar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.